Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > T2 Biosystems Raises $15 Million in Series C Financing

Abstract:
T2 Biosystems, Inc., a company developing the first decentralized clinical diagnostic solution that eliminates extensive sample preparation and enables rapid molecular and immunodiagnostic testing on a single instrument, today announced that it has raised approximately $15 million in a Series C financing. Proceeds from the financing will be used to accelerate the development and commercialization of T2 Biosystems' next generation diagnostic platform for use in the decentralized setting.

T2 Biosystems Raises $15 Million in Series C Financing

Cambridge, MA | Posted on May 25th, 2010

Physic Ventures led the round, joined by new investors Arcus Ventures, RA Capital, Camros Capital, WS Investments and existing investors, Flagship Ventures, Polaris Venture Partners, Flybridge Capital Partners and Partners Healthcare. T2 Biosystems previously raised $10.8 million in a Series B financing in 2008.

T2 Biosystems is developing the next generation of clinical diagnostic solutions through its proprietary technology, which combines nanotechnology and the miniaturization of proven magnetic resonance (MR) technology to eliminate the need for extensive sample preparation and enable rapid, accurate and portable diagnostics. T2 Biosystems' strategy is to develop a robust pipeline of products using its proprietary technology to enable the performance of molecular and immunoassay diagnostics on a small bench-top instrument in decentralized settings, including hospitals, diagnostic laboratories and medical offices.

The company has completed a fully functional alpha version of the commercial bench-top instrument and has developed a broad set of assays that demonstrates sensitivity, specificity, dynamic range and the precision equal or superior to large, specialized central lab analyzers. The company plans to launch the first of its commercial products to improve care of immunocompromised patients and will be working with industry partners to develop diagnostic tests for additional applications and to further advance the platform.

"This successful financing underscores the significant breakthroughs and value created by our team over the past two years" said John McDonough, CEO and President of T2 Biosystems. "Our mission is to revolutionize diagnostic testing by dramatically improving patient care and reducing overall healthcare costs by enabling immediate, accurate diagnostic testing in nearly any setting. The funding will allow us to advance and commercialize our initial menu of diagnostic tests in the decentralized setting where our unique technical advantages will improve disease diagnosis and treatment."

"T2 Biosystems' MR technology represents a novel approach for portable diagnostics, and T2's progress to date has been impressive," said Stacy Feld, Director at Physic Ventures. "T2 Biosystems is a strong fit with Physic's thesis to accelerate the personalized health agenda by enabling rapid, precise clinical diagnosis, thereby improving patient outcomes and reducing healthcare costs. I look forward to working with the company's outstanding management team and strong syndicate of existing investors to help bring T2's technology to the marketplace."

In connection with this financing, Ms. Feld will join the Board of Directors of T2 Biosystems, which is comprised of Michael Cima, Ph.D., Professor of Engineering, Material Science & Engineering, MIT; Alan Crane, General Partner, Polaris Venture Partners; Michael Greeley, General Partner, Flybridge Capital Partners; Robert Langer, D. Sc., Institute Professor, MIT; Stanley N. Lapidus, Chairman, Helicos Biosciences Corporation; Douglas A. Levinson, PhD, Partner, Flagship Ventures; and John McDonough, T2 Biosystems, Chief Executive Officer.

####

About T2 Biosystems
T2 Biosystems is a private biotechnology company developing next-generation clinical diagnostic products using its proprietary technology, combining nanotechnology and miniaturized magnetic resonance (MR) technology to eliminate extensive sample preparation and provide rapid, accurate and portable diagnostics. T2 Biosystems was founded in 2006 by renowned researchers from the Massachusetts Institute of Technology, Harvard University, Harvard Medical School and Massachusetts General Hospital, and has assembled a world-class team, board of directors and scientific advisory board that collectively have a proven track record of translating technologic innovations into breakthrough products, building significant corporate value. T2 Biosystems is located in Cambridge, Massachusetts. For more information, please visit the company's website at www.t2biosystems.com.

About Physic Ventures
Physic Ventures is the first venture capital firm dedicated to investing in keeping people healthy by providing capital and expertise to science-based, consumer-driven health and sustainable living companies. The firm's strategy is to capitalize on major economic, social and political trends shaping the landscape of personal and planetary health, including the rapid migration toward a consumer-driven, prevention-oriented "self-care" paradigm. Physic Ventures is based in San Francisco, CA. For more information, please visit Physic Ventures' website at www.physicventures.com.

For more information, please click here

Contacts:
T2 Biosystems, Inc.
286 Cardinal Medeiros Avenue
Cambridge, MA 02141
Phone: 617-661-8282
Fax: 617-876-1608

Copyright © T2 Biosystems

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Quantum networks: Back and forth are not equal distances! July 28th, 2015

Smart hydrogel coating creates 'stick-slip' control of capillary action July 27th, 2015

Industrial Nanotech, Inc. Provides Update on PCAOB Audited Financials July 27th, 2015

Global Corrosion Resistant Nano Coatings Market To 2015: Acute Market Reports July 27th, 2015

Investments/IPO's/Splits

Harris & Harris Group Portfolio Company, Bridgelux, Enters into Agreement to be Acquired by an Investment Group July 22nd, 2015

Harris & Harris Group Portfolio Company, OpGen, Gains $6 Million Investment From Merck GHI in Addition to New Acquisition July 16th, 2015

Harris & Harris Group Portfolio Company, AgBiome, Announces Partnership to Accelerate the Discovery of Next Generation Insect-Resistant Crops July 1st, 2015

Nanometrics to Participate in 7th Annual CEO Investor Summit 2015: Investor Event Held Concurrently With SEMICON West in San Francisco June 25th, 2015

Nanomedicine

Stretching the limits on conducting wires July 25th, 2015

UT Dallas nanotechnology research leads to super-elastic conducting fibers July 24th, 2015

Nanopaper as an optical sensing platform July 23rd, 2015

Albany College of Pharmacy and Health Sciences to Host One Week Symposium on Nanomedicine July 23rd, 2015

Announcements

Quantum networks: Back and forth are not equal distances! July 28th, 2015

Reshaping the solar spectrum to turn light to electricity: UC Riverside researchers find a way to use the infrared region of the sun's spectrum to make solar cells more efficient July 27th, 2015

Industrial Nanotech, Inc. Provides Update on PCAOB Audited Financials July 27th, 2015

Global Corrosion Resistant Nano Coatings Market To 2015: Acute Market Reports July 27th, 2015

Tools

Reshaping the solar spectrum to turn light to electricity: UC Riverside researchers find a way to use the infrared region of the sun's spectrum to make solar cells more efficient July 27th, 2015

Superfast fluorescence sets new speed record: Plasmonic device has speed and efficiency to serve optical computers July 27th, 2015

Ultra-thin hollow nanocages could reduce platinum use in fuel cell electrodes July 24th, 2015

Deben reports on the use of their CT500 in the X-ray microtomography laboratory at La Trobe University, Melbourne, Australia July 22nd, 2015

Appointments/Promotions/New hires/Resignations/Deaths

American Chemical Society expands reach to include rapidly emerging area of sensor science July 25th, 2015

BESSTECH Names Doug Grose as Chief Technology Officer: Former GLOBALFOUNDRIES CEO to drive technology roadmap and strategic partnerships for emerging lithium-ion battery component company July 14th, 2015

A cool way to form 2-D conducting polymers using ice: POSTECH scientists develop breakthrough technique to easily optimize electrical properties of Polyaniline nanosheets to an unprecedented level in an environmental-friendly and inexpensive way July 7th, 2015

Angstron Materials Appoints VP for Business Development And Engineering June 27th, 2015

Nanobiotechnology

Spintronics: Molecules stabilizing magnetism: Organic molecules fixing the magnetic orientation of a cobalt surface/ building block for a compact and low-cost storage technology/ publication in Nature Materials July 25th, 2015

Programming adult stem cells to treat muscular dystrophy and more by mimicking nature July 22nd, 2015

Biophotonics - Global Strategic Business Report 2015 July 21st, 2015

Rare form: Novel structures built from DNA emerge July 20th, 2015

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project